An HIV Vaccine Is on the Horizon

The genome of HIV-1 has been identified by a research team in Zurich, Switzerland.¹

“Understanding the determinants of broadly neutralizing antibody (bNAb) evolution is crucial for the development of bNAb-based HIV vaccines,” the team wrote.¹

IF YOU LIKE THIS, READ MORE...

In HIV, Antibody Prohibits Natural Immune Response

HIV Antiviral Shows Good Metabolic Effects

Over the years, the team has identified how the virus load and diversity of the virus, the duration of infection, and the ethnicity of the infected individual can affect the body’s immune response.

For their new study, the team evaluated patient data and blood samples from about 4500 HIV-positive individuals registered in the Swiss HIV Cohort Study and the Zurich Primary HIV Infection Study.

They identified and compared 303 potential transmission pairs and analyzed the influence of viral antigens in shaping antibody responses.

“By comparing the immune response of these pairs of patients, we were able to show that the HI virus itself has an influence on the extent and specificity of the antibody reactions,” said Roger Kouyos, lead author on the study and research group leader at the Department of Infectious Diseases and Hospital Epidemiology at University Hospital Zurich.²

Now, with this new piece of evidence, the team hopes to start developing a vaccine for HIV-1.

“We introduce the concept of bNAb-imprinting viruses and provide evidence for the existence of such viruses in a systematic screening of our cohort,” the researchers conclude.¹

“The bNAb-imprinting capacity can be substantial, as indicated by a transmission pair with highly similar HIV-1 antibody responses and strong bNAb activity. Identification of viruses that have bNAb-imprinting capacities and their characterization may thus provide the potential to develop lead immunogens.”

—Amanda Balbi

References:

1. Kouyos RD, Rusert P, Kadelka C, et al; The Swiss HIV Cohort Study. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses [published online September 10, 2018]. Nature. doi:10.1038/s41586-018-0517-0.
2. Special Antibodies Could Lead to HIV Vaccine [press release]. Zurich, Switzerland: University of Zurich; September 10, 2018. https://www.media.uzh.ch/en/Press-Releases/2018/HIV-Vaccine.html. Accessed September 17, 2018.